HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma.
暂无分享,去创建一个
N. Sneige | A. Sahin | N. Ordóñez | M. Hoang | N Sneige | M P Hoang | A A Sahin | N G Ordòñez | Nelson G. Ordóñez | Aysegul A. Sahin | Mai P. Hoang
[1] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[2] S. Edge,et al. Treatment of early-stage breast cancer. , 1999, Current problems in cancer.
[3] W. Gullick. 4. The role of the epidermal growth factor receptor and the c‐erbB‐2 protein in breast cancer , 1990 .
[4] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .
[5] J. Fleiss. Statistical methods for rates and proportions , 1974 .
[6] D Tripathy,et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Graziano. HER-2 breast assay, linked to Herceptin, wins FDA's okay. , 1998, CAP today.
[8] M. Kraus,et al. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. , 1989, Genomics.
[9] D. Slamon,et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.
[10] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[11] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.
[12] D. Horsfall,et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] T. Fleming,et al. Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial , 1998 .
[14] C. McNeil. How should HER2 status be determined? , 1999, Journal of the National Cancer Institute.
[15] D. Slamon,et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Persons Dl,et al. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .
[17] S J Schnitt,et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Cori Bargmann,et al. The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.